CA2712087A1 - Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib - Google Patents

Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib Download PDF

Info

Publication number
CA2712087A1
CA2712087A1 CA2712087A CA2712087A CA2712087A1 CA 2712087 A1 CA2712087 A1 CA 2712087A1 CA 2712087 A CA2712087 A CA 2712087A CA 2712087 A CA2712087 A CA 2712087A CA 2712087 A1 CA2712087 A1 CA 2712087A1
Authority
CA
Canada
Prior art keywords
imatinib
patient
cmin
kit
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2712087A
Other languages
English (en)
French (fr)
Inventor
Yanfeng Wang
Elisabeth Wehrle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2712087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2712087A1 publication Critical patent/CA2712087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2712087A 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib Abandoned CA2712087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23
US61/022,945 2008-01-23
PCT/US2009/031510 WO2009094360A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Publications (1)

Publication Number Publication Date
CA2712087A1 true CA2712087A1 (en) 2009-07-30

Family

ID=40435094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2712087A Abandoned CA2712087A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Country Status (14)

Country Link
US (3) US20100298338A1 (enExample)
EP (1) EP2237783B1 (enExample)
JP (2) JP5936821B2 (enExample)
KR (1) KR101579993B1 (enExample)
CN (1) CN101951910B (enExample)
AU (1) AU2009206566A1 (enExample)
BR (1) BRPI0906504A2 (enExample)
CA (1) CA2712087A1 (enExample)
ES (1) ES2526537T3 (enExample)
MX (1) MX2010008103A (enExample)
PL (1) PL2237783T3 (enExample)
PT (1) PT2237783E (enExample)
RU (1) RU2537223C2 (enExample)
WO (1) WO2009094360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
SI1686997T1 (sl) * 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
MX2009003082A (es) * 2006-09-22 2009-04-01 Novartis Ag Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl.
US8119841B2 (en) 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate

Also Published As

Publication number Publication date
RU2537223C2 (ru) 2014-12-27
US20100298338A1 (en) 2010-11-25
ES2526537T3 (es) 2015-01-13
PL2237783T3 (pl) 2015-04-30
EP2237783A1 (en) 2010-10-13
KR20100105778A (ko) 2010-09-29
US20160045501A1 (en) 2016-02-18
US20170035757A1 (en) 2017-02-09
PT2237783E (pt) 2014-12-23
US9763944B2 (en) 2017-09-19
BRPI0906504A2 (pt) 2015-07-14
JP2011510086A (ja) 2011-03-31
RU2010134916A (ru) 2012-02-27
CN101951910B (zh) 2013-07-17
JP5881671B2 (ja) 2016-03-09
JP2014094946A (ja) 2014-05-22
MX2010008103A (es) 2010-08-23
JP5936821B2 (ja) 2016-06-22
KR101579993B1 (ko) 2015-12-23
WO2009094360A1 (en) 2009-07-30
AU2009206566A1 (en) 2009-07-30
CN101951910A (zh) 2011-01-19
EP2237783B1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
JP2025111571A (ja) 消化管間質腫瘍の治療のための併用療法
US20120202836A1 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
EA028062B1 (ru) Лечение рака ингибиторами tor киназы
JP2009532438A5 (enExample)
JP4499359B2 (ja) シグナル変換阻害剤とエポチロン誘導体とを含有してなる組合せ剤
JP2023524789A5 (enExample)
TW201006823A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
JP2021522246A (ja) 癌治療のための併用
WO2018092064A1 (en) Combinations of mdm2 inhibitors and bcl-xl inhibitors
JP2019530711A5 (enExample)
US9763944B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US20240269136A1 (en) Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
US20080200489A1 (en) Combination of Organic Compounds
CA2552759A1 (en) Combination of organic compounds
RU2695362C2 (ru) Новое сочетание з-[(3-{ [4-(4-морфолинилметил)-1н-пиррол-2-ил]метилен} -2-оксо-2,3-дигидро-1н-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
RU2774612C2 (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk
JP5751568B2 (ja) 悪性末梢神経鞘腫瘍の処置
TW201817420A (zh) 治療或緩解慢性骨髓性白血病用之醫藥組合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140120

FZDE Discontinued

Effective date: 20190820